Denmark· DK-28104960311
Tresiba 100 Penfill
A insulin degludec product containing insulin degludec, registered in Denmark by Novo Nordisk A/S. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Insulin degludec is registered in 14 of 19 countries.
Countries holding a registration under ATC A10AE06 (insulin degludec), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Insulin degludec · ATC A10AE06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Insulin degludec
- Manufacturer
- Novo Nordisk A/S
- Country
- Denmark (DK)
- ATC code
- A10AE06
- ATC class
- Insulin degludec
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28104960311
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
431 interactions on record for insulin degludec.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Insulin degludec · interactions on record
431 records
- 15 severe
- 366 moderate
- 50 minor
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- PrednisoloneA07EA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A10AE06
Insulin degludec, as other registers publish it.
- United StatesInsulin DegludecNovo Nordisk Pharma, Inc.
- United StatesInsulin DegludecA-S Medication Solutions
- United StatesInsulin DegludecNovo Nordisk Pharma, Inc.
- United StatesInsulin DegludecNovo Nordisk Pharma, Inc.
- United StatesInsulin DegludecNovo Nordisk Pharma, Inc.
- United StatesInsulin DegludecNovo Nordisk Pharma, Inc.
- United StatesInsulin DegludecA-S Medication Solutions
- United StatesInsulin DegludecNovo Nordisk Pharma, Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e2130749-1d2d-4c27-872b-dec952cf40c9 GET /v1/drugs/e2130749-1d2d-4c27-872b-dec952cf40c9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "injektionsvæske, opløsning i cylinderampul",
"source": "dkma",
"strength": "100 E/ml",
"auth_role": "CO-RAP",
"dk_drugid": "28104960311",
"substance": "Insulin degludec",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "41295"
}See everything about insulin degludec.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.